BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 190] [Cited by in F6Publishing: 207] [Article Influence: 63.3] [Reference Citation Analysis]
Number Citing Articles
1 Yuan W, Zhao H, Zhou A, Wang S. Interference of EFNA4 suppresses cell proliferation, invasion and angiogenesis in hepatocellular carcinoma by downregulating PYGO2. Cancer Biology & Therapy 2022;23:1-12. [DOI: 10.1080/15384047.2022.2149039] [Reference Citation Analysis]
2 Li X, Zhang Y, Ma W, Li J. An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/6141317] [Reference Citation Analysis]
3 Rizzo A, Carloni R, Ricci AD, Cusmai A, Laforgia M, Calabrò C, Ungaro V, Oreste D, Sollitto M, Palmiotti G, Brandi G. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety 2022. [DOI: 10.1080/14740338.2023.2152793] [Reference Citation Analysis]
4 Chen Y, Jiang Y, Huang X, Chen L, Yang H, Zhao J, Liang B. Cordycepin Inhibits the Growth of Hepatocellular Carcinoma by Regulating the Pathway of Aerobic Glycolysis. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-14. [DOI: 10.1155/2022/6454482] [Reference Citation Analysis]
5 Shi F, Huang C, Ren Y, Deng C, Sun N, Shen X. Multiscale Element-Doped Nanowire Array-Coupled Machine Learning Reveals Metabolic Fingerprints of Nonreversible Liver Diseases. Anal Chem 2022. [DOI: 10.1021/acs.analchem.2c03743] [Reference Citation Analysis]
6 Zhao J, Li R, Li J, Chen Z, Lin Z, Zhang B, Deng L, Chen G, Wang Y. CAFs-derived SCUBE1 promotes malignancy and stemness through the Shh/Gli1 pathway in hepatocellular carcinoma. J Transl Med 2022;20:520. [DOI: 10.1186/s12967-022-03689-w] [Reference Citation Analysis]
7 Xia F, Huang Z, Zhang Q, Ndhlovu E, Chen X, Zhang B, Zhu P. Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact? European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.11.005] [Reference Citation Analysis]
8 Du Y, Shan C, You Y, Chen M, Zhu L, Shu G, Han G, Wu L, Ji J, Yu H, Du Y. NIR-Ⅱ Fluorescence Imaging-Guided Hepatocellular Carcinoma Treatment via IR-1061-Acridine and Lenvatinib Co-loaded Thermal-Sensitive Micelles and Anti-PD-1 Combinational Therapy. Chemical Engineering Journal 2022. [DOI: 10.1016/j.cej.2022.140437] [Reference Citation Analysis]
9 Qiao W, Wang Q, Hu C, Zhang Y, Li J, Sun Y, Yuan C, Wang W, Liu B, Zhang Y. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1019772] [Reference Citation Analysis]
10 Feng H, Zhuo Y, Zhang X, Li Y, Li Y, Duan X, Shi J, Xu C, Gao Y, Yu Z. Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. J Hepatocell Carcinoma 2022;9:1109-25. [PMID: 36320666 DOI: 10.2147/JHC.S381764] [Reference Citation Analysis]
11 Thormann M, Surov A, Pech M, March C, Hass P, Damm R, Omari J. Local ablation of hepatocellular carcinoma by interstitial brachytherapy: prediction of outcome by diffusion-weighted imaging. Acta Radiol 2022;:2841851221129714. [PMID: 36262039 DOI: 10.1177/02841851221129714] [Reference Citation Analysis]
12 Wu Q, Chen Z, Ding Y, Tang Y, Cheng Y. Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis. Front Nutr 2022;9:1033129. [DOI: 10.3389/fnut.2022.1033129] [Reference Citation Analysis]
13 Hu B, Qian X, Qian P, Xu G, Jin X, Chen D, Xu L, Tang J, Wu W, Li W, Zhang J. Advances in the functions of CTRP6 in the development and progression of the malignancy. Front Genet 2022;13:985077. [DOI: 10.3389/fgene.2022.985077] [Reference Citation Analysis]
14 Wang Y, Peng B, Ning C, He S, Yang H, Mao Y, Sun L. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy. Front Immunol 2022;13:966167. [DOI: 10.3389/fimmu.2022.966167] [Reference Citation Analysis]
15 Wang H, Zhang Y, Yan L, Lv Q, Lu J, Yun B. Analysis of TRIM27 prognosis value and immune infiltrates in hepatocellular carcinoma. Int J Immunopathol Pharmacol 2022;36:3946320221132986. [PMID: 36217828 DOI: 10.1177/03946320221132986] [Reference Citation Analysis]
16 Xu L, Li G, Yang B. Establishment of a risk assessment system for complications of hepatectomy based on preoperative variables. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.09.004] [Reference Citation Analysis]
17 Gu DY, Zhang Y, Hu JX, Qin HY, Lu X, He GB, Shang L. The value of contrast-enhanced ultrasound quantitative parameters in the prognosis prediction of hepatocellular carcinoma after thermal ablation: a retrospective cohort study. J Gastrointest Oncol 2022;13:2522-31. [PMID: 36388675 DOI: 10.21037/jgo-22-919] [Reference Citation Analysis]
18 Pu Q, Yu L, Wang X, Yan H, Xie Y, Jiang Y, Yang Z. Immunomodulatory Effect of Traditional Chinese Medicine Combined with Systemic Therapy on Patients with Liver Cancer: A Systemic Review and Network Meta-analysis. J Cancer 2022;13:3280-96. [PMID: 36118529 DOI: 10.7150/jca.74829] [Reference Citation Analysis]
19 Zhang W, Wan Y, Zhang Y, Liu Q, Zhu X. CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma. Cancer Manag Res 2022;14:2691-709. [PMID: 36117731 DOI: 10.2147/CMAR.S359545] [Reference Citation Analysis]
20 Mohapatra P, Chandrasekaran N. Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review. Biomed Pharmacother 2022;155:113713. [PMID: 36126453 DOI: 10.1016/j.biopha.2022.113713] [Reference Citation Analysis]
21 Mo J, Da X, Li Q, Huang J, Lu L, Lu H, Liao R. The Study of Exosomes-Encapsulated mPEG-PLGA Polymer Drug-Loaded Particles for Targeted Therapy of Liver Cancer. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/4234116] [Reference Citation Analysis]
22 Kim M, Hui KM, Shi M, Reau N, Aloman C. Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 36097402 DOI: 10.1002/hep4.2079] [Reference Citation Analysis]
23 Cao X, Chen H, Li Z, Li X, Yang X, Jin Q, Liang Y, Zhang J, Zhou M, Zhang N, Chen G, Du H, Zao X, Ye Y. Network pharmacology and in vitro experiments-based strategy to investigate the mechanisms of KangXianYiAi formula for hepatitis B virus-related hepatocellular carcinoma. Front Pharmacol 2022;13:985084. [DOI: 10.3389/fphar.2022.985084] [Reference Citation Analysis]
24 Xu Y, Liu R. Analysis of the role of m6A and lncRNAs in prognosis and immunotherapy of hepatocellular carcinoma. Heliyon 2022;8:e10612. [PMID: 36158075 DOI: 10.1016/j.heliyon.2022.e10612] [Reference Citation Analysis]
25 Xie Y, Yan F, Wang X, Yu L, Yan H, Pu Q, Li W, Yang Z. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma. Cancer Med 2022. [PMID: 36043445 DOI: 10.1002/cam4.5064] [Reference Citation Analysis]
26 Lu J, Cao W, He Z, Wang H, Hao J, Xu J, Liao R. A Genomic Instability-Related Long Noncoding RNA Signature for Predicting Hepatocellular Carcinoma Prognosis. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/3090523] [Reference Citation Analysis]
27 Su C, Wang W, Mo J, Liu F, Zhang H, Liu Y, Chen X, Liao Z, Zhang B, Zhu P. Long noncoding RNA HOXC-AS3 interacts with CDK2 to promote proliferation in hepatocellular carcinoma. Biomark Res 2022;10. [DOI: 10.1186/s40364-022-00411-2] [Reference Citation Analysis]
28 Xing Y, Hu Y, Zou H, Xie H, Jiang T, Liu L. A novel O2- (2,4-dinitrophenyl) diazeniumdiolate inhibits hepatocellular carcinoma migration, invasion, and EMT through the Wnt/β-catenin pathway. Toxicol In Vitro 2022;84:105456. [PMID: 35985571 DOI: 10.1016/j.tiv.2022.105456] [Reference Citation Analysis]
29 Kalpadakis S, Sifaki-pistolla D, Symvoulakis EK, Kelefiotis-stratidakis P, Vamvakas L, Mavroudis D, Lionis C. Reporting Liver Cancer Trends in the Island of Crete, Greece: Results from a Geo-Epidemiological Study. IJERPH 2022;19:10166. [DOI: 10.3390/ijerph191610166] [Reference Citation Analysis]
30 Tan XP, Xiong BH, Zhang YX, Wang SL, Zuo Q, Li J. FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. Eur J Pharmacol 2022;931:175186. [PMID: 35977595 DOI: 10.1016/j.ejphar.2022.175186] [Reference Citation Analysis]
31 Su Q, Zhang S, Ran J. Identification of a Novel PPAR Signature for Predicting Prognosis and Immune Microenvironment in Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-1943906/v1] [Reference Citation Analysis]
32 Liu C, Huang R, Yu H, Gong Y, Wu P, Feng Q, Li X. Fuzheng Xiaozheng prescription exerts anti-hepatocellular carcinoma effects by improving lipid and glucose metabolisms via regulating circRNA-miRNA-mRNA networks. Phytomedicine 2022;103:154226. [DOI: 10.1016/j.phymed.2022.154226] [Reference Citation Analysis]
33 Zhou K, Jiang Y, Feng S, Wang T, Wang L, Cao J, Jiao Y. Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. Radiation Medicine and Protection 2022. [DOI: 10.1016/j.radmp.2022.07.005] [Reference Citation Analysis]
34 Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao H, Guo H, Sun S, Li M, Zhao D, Li X, Qi W, Zhang Y. Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chin Med 2022;17:90. [PMID: 35907976 DOI: 10.1186/s13020-022-00645-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Rao Z, Li H, Yao W, Wang Q, Ma B, Xue D, Meng X. A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC. Front Oncol 2022;12:927468. [DOI: 10.3389/fonc.2022.927468] [Reference Citation Analysis]
36 Hu B, Gao J, Shi J, Zhang F, Shi C, Wen P, Wang Z, Guo W, Zhang S. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma. Front Immunol 2022;13:970117. [DOI: 10.3389/fimmu.2022.970117] [Reference Citation Analysis]
37 Zhang W, Wu W, Meng Q, Yang L, Yuan J, Tian Z, Ding R, Zhang X, Wang J, Tao K. Research Progress on Long Noncoding RNAs and N6-Methyladenosine in Hepatocellular Carcinoma. Front Oncol 2022;12:907399. [DOI: 10.3389/fonc.2022.907399] [Reference Citation Analysis]
38 Ding F, Li J, Zhang Y, Wang C, Yu Y, Isaguliants M. Identifying a Novel Endoplasmic Reticulum-Related Prognostic Model for Hepatocellular Carcinomas. Oxidative Medicine and Cellular Longevity 2022;2022:1-24. [DOI: 10.1155/2022/8248355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Zhang Y, Qin S, Chao J, Luo Y, Sun Y, Duan J. The In-Vitro Antitumor Effects of AST-3424 Monotherapy and Combination Therapy With Oxaliplatin or 5-Fluorouracil in Primary Liver Cancer. Front Oncol 2022;12:885139. [DOI: 10.3389/fonc.2022.885139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Cai Q, Duan J, Ding L. Prognostic model of immune-related genes for patients with hepatocellular carcinoma. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.819491] [Reference Citation Analysis]
41 Liu P, Zhang X, Fu Q, Liu C, Luo Q, Yu P, Chen S, Zhang H, Qin T, Zhang Y. LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/9313680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zheng J, Liu J, Zhu T, Liu C, Gao Y, Dai W, Zhuo W, Mao X, He B, Liu Z. Effects of Glycolysis-Related Genes on Prognosis and the Tumor Microenvironment of Hepatocellular Carcinoma. Front Pharmacol 2022;13:895608. [DOI: 10.3389/fphar.2022.895608] [Reference Citation Analysis]
43 Zhang Y, Pang S, Sun B, Zhang M, Jiao X, Lai L, Qian Y, Yang N, Yang W. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:884066. [DOI: 10.3389/fonc.2022.884066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Gatti M, Maino C, Darvizeh F, Serafini A, Tricarico E, Guarneri A, Inchingolo R, Ippolito D, Ricardi U, Fonio P, Faletti R. Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment. World J Gastroenterol 2022; 28(26): 3116-3131 [DOI: 10.3748/wjg.v28.i26.3116] [Reference Citation Analysis]
45 Gao Y, Li Y, Song Z, Jin Z, Li X, Yuan C, Yang D. Sortilin 1 Promotes Hepatocellular Carcinoma Cell Proliferation and Migration by Regulating Immune Cell Infiltration. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/6509028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Zhang Y, Wang X, Wang H, Jiang Y, Xu Z, Luo L. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:893107. [DOI: 10.3389/fonc.2022.893107] [Reference Citation Analysis]
47 Wu C, Tian S, Guo Y, Yu C, Lei L, Zheng D, Xie H, Zheng J, Sun C. circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway. J Immunol Res 2022;2022:8649386. [PMID: 35769514 DOI: 10.1155/2022/8649386] [Reference Citation Analysis]
48 Liu S, Huang F, Ru G, Wang Y, Zhang B, Chen X, Chu L. Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application. Front Oncol 2022;12:902820. [DOI: 10.3389/fonc.2022.902820] [Reference Citation Analysis]
49 Zhao J, Zeng G, Lin E, Cai C, Li P, Zou B, Li J. Combined HIF-1α and SHH Up-Regulation Is a Potential Biomarker to Predict Poor Prognosis in Postoperative Hepatocellular Carcinoma. J Invest Surg 2022;:1-8. [PMID: 35768071 DOI: 10.1080/08941939.2022.2090034] [Reference Citation Analysis]
50 Zhao J, Guo J, Wang Y, Ma Q, Shi Y, Cheng F, Lu Q, Fu W, Ouyang G, Zhang J, Xu Q, Hu X. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Front Oncol 2022;12:920287. [DOI: 10.3389/fonc.2022.920287] [Reference Citation Analysis]
51 Yu S, Li Z, Tu L, Pu Y, Yan D, Wang X, Zheng X, Yu J. Uricase sensitizes hepatocellular carcinoma cells to 5-fluorouracil through uricase-uric acid-UMP synthase axis. J Physiol Biochem 2022. [PMID: 35674867 DOI: 10.1007/s13105-022-00894-5] [Reference Citation Analysis]
52 Li XM, Chen WB, Zhang J, Ma LF, Li Q, Feng C, Yuan XH, Kang LQ. Correlation of CT Perfusion Parameters and Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (BFGF) in Patients with Primary Liver Cancer. Evid Based Complement Alternat Med 2022;2022:4548922. [PMID: 35656468 DOI: 10.1155/2022/4548922] [Reference Citation Analysis]
53 Liu Y, Zhang Y, Du D, Gu X, Zhou S. PCDH17 is regulated by methylation of DNMT3B and affects the malignant biological behavior of HCC through EMT. Experimental Cell Research 2022. [DOI: 10.1016/j.yexcr.2022.113245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Huang Y, Wang T, Yang J, Wu X, Fan W, Chen J. Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review. Int J Nanomedicine 2022;17:2335-52. [PMID: 35619893 DOI: 10.2147/IJN.S363456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Li G, Tian Y, Gao Z, Ma X, Ren C. Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network. Biochem Genet 2022. [PMID: 35633444 DOI: 10.1007/s10528-022-10235-2] [Reference Citation Analysis]
56 Ma S, Adzavon YM, Wen X, Zhao P, Xie F, Liu M, Ma X. Novel Insights in the Regulatory Mechanisms of Ferroptosis in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:873029. [DOI: 10.3389/fcell.2022.873029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Ren F, Zhang Y, Qin Y, Shang J, Wang Y, Wei P, Guo J, Jia H, Zhao T. Taraxasterol prompted the anti-tumor effect in mice burden hepatocellular carcinoma by regulating T lymphocytes. Cell Death Discov 2022;8:264. [PMID: 35577774 DOI: 10.1038/s41420-022-01059-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wu Y, Xu X, Liu M, Qin X, Wu Q, Ding H, Zhao Q. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis. Biochem Pharmacol 2022;:115093. [PMID: 35580648 DOI: 10.1016/j.bcp.2022.115093] [Reference Citation Analysis]
59 Li W, Liu J, Zhang D, Gu L, Zhao H. The Prognostic Significance and Potential Mechanism of Ferroptosis-Related Genes in Hepatocellular Carcinoma. Front Genet 2022;13:844624. [PMID: 35559035 DOI: 10.3389/fgene.2022.844624] [Reference Citation Analysis]
60 Sun Y, Sun Y, Li S, Tao X, Cai L. Zhenzhu Xiaoji Decoction Induces Autophagy and Apoptosis Cell Death in Liver Cancer Cells through AKT/mTOR and JAK2/STAT3 Signaling Pathway. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-13. [DOI: 10.1155/2022/4445293] [Reference Citation Analysis]
61 Jiang L, Li H, Zhao D, Li W. A Prognostic Model for Patients with Hepatocellular Carcinoma Based on Hypoxia-Related Long Noncoding RNAs. Journal of Nanomaterials 2022;2022:1-10. [DOI: 10.1155/2022/4642477] [Reference Citation Analysis]
62 Hawash M, Kahraman DC, Olgac A, Ergun SG, Hamel E, Cetin-atalay R, Baytas SN. Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents. Journal of Molecular Structure 2022;1254:132345. [DOI: 10.1016/j.molstruc.2022.132345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
63 Song S, Yu Z, You Y, Liu C, Xie X, Lv H, Xiao F, Zhu Q, Qin C. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis 2022;13:351. [DOI: 10.1038/s41419-022-04796-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z, Huang X, Liu H, Hou J, Zhang X, Zhu W. Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:813275. [DOI: 10.3389/fonc.2022.813275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Lai X, Wu Y, Hong G, Li J, Luo Q, Yuan J, Dai G, Liu S, Feng H, Wang F. A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9117205] [Reference Citation Analysis]
66 d’Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology 2022;29:2422-34. [DOI: 10.3390/curroncol29040196] [Reference Citation Analysis]
67 Li Y, Xiong H. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways. BMC Cancer 2022;22:298. [PMID: 35313850 DOI: 10.1186/s12885-022-09398-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Wei Q, Guo JS. Developing natural marine products for treating liver diseases. World J Clin Cases 2022; 10(8): 2369-2381 [DOI: 10.12998/wjcc.v10.i8.2369] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zhao L, Zhang W, Wu Q, Fu C, Ren X, Lv K, Ma T, Chen X, Tan L, Meng X. Lanthanide europium MOF nanocomposite as the theranostic nanoplatform for microwave thermo-chemotherapy and fluorescence imaging. J Nanobiotechnology 2022;20:133. [PMID: 35292037 DOI: 10.1186/s12951-022-01335-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Xia F, Huang Z, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy. BMC Surg 2022;22. [DOI: 10.1186/s12893-022-01537-8] [Reference Citation Analysis]
71 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
72 Zhang K, Barry AE, Lamm R, Patel K, Schafer M, Dang H. The role of RNA binding proteins in hepatocellular carcinoma. Adv Drug Deliv Rev 2022;182:114114. [PMID: 35063534 DOI: 10.1016/j.addr.2022.114114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Xin Z, Li J, Zhang H, Zhou Y, Song J, Chen P, Bai L, Chen H, Zhou J, Chen J, Ying B. Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. Front Oncol 2022;12:783109. [PMID: 35155229 DOI: 10.3389/fonc.2022.783109] [Reference Citation Analysis]
74 Li S, Chen L. Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma. Front Oncol 2022;12:793432. [PMID: 35155236 DOI: 10.3389/fonc.2022.793432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis 2022;13:146. [PMID: 35165269 DOI: 10.1038/s41419-022-04583-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
76 Lee TY, Choi HJ, Ahn J, Hong TH, You Y. Efficacy of Tumor Markers After Liver Transplantation In Patients With Hepatocellular Carcinoma. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.01.007] [Reference Citation Analysis]
77 Hai Y, Geng J, Li P, Ma W, Wang C, Wei M, Hou X, Chen G, Gu Y, Liu M, Shao C. Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114166] [Reference Citation Analysis]
78 Ouyang X, Lv L, Zhao Y, Zhang F, Hu Q, Li Z, Zhu D, Li L. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. Front Oncol 2021;11:801506. [PMID: 35087760 DOI: 10.3389/fonc.2021.801506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Zhang M, Zhao H, Gao H. Interleukin-24 Limits Tumor-Infiltrating T Helper 17 Cell Response in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Viral Immunology. [DOI: 10.1089/vim.2021.0174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Feng G, Cheng Y, Chen K, Shi Z, Solimando AG. Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-12. [DOI: 10.1155/2022/5969716] [Reference Citation Analysis]
81 Tang Q, Li X, Chen Y, Long S, Yu Y, Sheng H, Wang S, Han L, Wu W. Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway. Mol Carcinog 2022. [PMID: 35040191 DOI: 10.1002/mc.23389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
82 Deng P, Li M, Wu Y. The Predictive Efficacy of Serum Exosomal microRNA-122 and microRNA-148a for Hepatocellular Carcinoma Based on Smart Healthcare. J Healthc Eng 2022;2022:5914541. [PMID: 35028121 DOI: 10.1155/2022/5914541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Liu W, Quan B, Lu S, Tang B, Li M, Chen R, Ren Z, Yin X. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Front Oncol 2021;11:771045. [PMID: 35004289 DOI: 10.3389/fonc.2021.771045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Pan G, Zhang J, You F, Cui T, Luo P, Wang S, Li X, Yuan Q. ETS Proto-Oncogene 1-activated muskelin 1 antisense RNA drives the malignant progression of hepatocellular carcinoma by targeting miR-22-3p to upregulate ETS Proto-Oncogene 1. Bioengineered 2022;13:1346-58. [PMID: 34983308 DOI: 10.1080/21655979.2021.2017565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
85 Hawash M, Kahraman DC, Ergun SG, Cetin-Atalay R, Baytas SN. Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines. BMC Chem 2021;15:66. [PMID: 34930409 DOI: 10.1186/s13065-021-00793-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Xu Y, Zhang M, Zhang Q, Yu X, Sun Z, He Y, Guo W. Role of Main RNA Methylation in Hepatocellular Carcinoma: N6-Methyladenosine, 5-Methylcytosine, and N1-Methyladenosine. Front Cell Dev Biol 2021;9:767668. [PMID: 34917614 DOI: 10.3389/fcell.2021.767668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
87 Zhang X, Svn Z, Liv M, Liu M, Zhang Y, Sun Q. Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies. Front Med (Lausanne) 2021;8:756210. [PMID: 34901068 DOI: 10.3389/fmed.2021.756210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Zhao S, Wei C, Tang H, Ding H, Han B, Chen S, Song X, Gu Q, Zhang Y, Liu W, Wang J. Elevated DNA Polymerase Delta 1 Expression Correlates With Tumor Progression and Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. Front Oncol 2021;11:736363. [PMID: 34868924 DOI: 10.3389/fonc.2021.736363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Yao Z, Wen S, Luo J, Hao W, Liang W, Chen Y. Establishment and Validation of an MTORC1 Signaling-Related Gene Signature to Predict Overall Survival in Patients with Hepatocellular Carcinoma. Biomed Res Int 2021;2021:6299472. [PMID: 34853791 DOI: 10.1155/2021/6299472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Wang L, Zhang W, Yang T, He L, Liao Y, Lu J. Construction and Comprehensive Analysis of a Stratification System Based on AGTRAP in Patients with Hepatocellular Carcinoma. Dis Markers 2021;2021:6144476. [PMID: 34840632 DOI: 10.1155/2021/6144476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Gao L, Xue J, Liu X, Cao L, Wang R, Lei L. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. Aging (Albany NY) 2021;13:24866-81. [PMID: 34839280 DOI: 10.18632/aging.203721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [PMID: 34887643 DOI: 10.3748/wjg.v27.i43.7462] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
93 Han Z, Li K, Wu J, Wang K, Qiu C, Ye H, Cui C, Song C, Wang K, Shi J, Wang P, Zhang J. Diagnostic value of RNA for hepatocellular carcinoma: a network meta-analysis. Biomark Med 2021;15:1755-67. [PMID: 34783583 DOI: 10.2217/bmm-2021-0327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, Peng T. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. J Hepatocell Carcinoma 2021;8:1323-38. [PMID: 34765572 DOI: 10.2147/JHC.S335425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Liu X, Liu Y, Liu Z, Zhang Y, Ma Y, Bai J, Yao H, Wang Y, Zhao X, Li R, Song X, Chen Y, Feng Z, Wang L. Identification of SLITRK6 as a Novel Biomarker in hepatocellular carcinoma by comprehensive bioinformatic analysis. Biochem Biophys Rep 2021;28:101157. [PMID: 34754951 DOI: 10.1016/j.bbrep.2021.101157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Wang Y, Li P, Mao S, Mo Z, Cao Z, Luo J, Zhou M, Liu X, Zhang S, Yu L. Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma. Front Pharmacol 2021;12:757194. [PMID: 34744733 DOI: 10.3389/fphar.2021.757194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
97 Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Jiang X, Zhang W, Li L, Xie S. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Pathol Oncol Res 2021;27:1609985. [PMID: 34737677 DOI: 10.3389/pore.2021.1609985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Lai E, Tai Y, Jiang J, Zhao C, Xiao Y, Quan X, Wu H, Gao J. Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma. J Cell Mol Med 2021;25:11128-41. [PMID: 34726341 DOI: 10.1111/jcmm.17035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Chen E, Zhou B, Bian S, Ni W, Chen Z. The lncRNA B3GALT5-AS1 Functions as an HCC Suppressor by Regulating the miR-934/UFM1 Axis. J Oncol 2021;2021:1776432. [PMID: 34721576 DOI: 10.1155/2021/1776432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Guo C, Guo X, Rong Y, Guo Y, Zhang L. Gene Expression Characteristics of Liver Tissue Reveal the Underlying Pathogenesis of Hepatocellular Carcinoma. Biomed Res Int 2021;2021:9458328. [PMID: 34651050 DOI: 10.1155/2021/9458328] [Reference Citation Analysis]
102 Lawal G, Xiao Y, Rahnemai-Azar AA, Tsilimigras DI, Kuang M, Bakopoulos A, Pawlik TM. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel) 2021;9:1184. [PMID: 34696292 DOI: 10.3390/vaccines9101184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
103 Jin Y, Zhang Y, Luo X. circRNA_PTPRA functions as a sponge of miR-582-3p to regulate hepatocellular carcinoma cell proliferation, migration, invasion and apoptosis. Exp Ther Med 2021;22:1276. [PMID: 34594413 DOI: 10.3892/etm.2021.10711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Feng Y, Wei G, Zhang L, Zhou H, Wang W, Guo P, Cheng C, Ji L, Cai Q, Feng Y, Tu H. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis. Bioengineered 2021;12:8217-32. [PMID: 34596006 DOI: 10.1080/21655979.2021.1982272] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
105 Reska D, Czajkowski M, Jurczuk K, Boldak C, Kwedlo W, Bauer W, Koszelew J, Kretowski M. Integration of solutions and services for multi-omics data analysis towards personalized medicine. Biocybernetics and Biomedical Engineering 2021;41:1646-63. [DOI: 10.1016/j.bbe.2021.10.005] [Reference Citation Analysis]
106 Lim MS, Goh GB, Chang JP, Low JK, Shelat VG, Huey TC, Dan YY, Kow A, Shridhar I, Tan PS, Junnarkar SP, Tan CK. A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open 2021;5:1015-8. [PMID: 34584969 DOI: 10.1002/jgh3.12624] [Reference Citation Analysis]
107 Yuan X, Zhao Q, Zhang Y, Xue M. The role and mechanism of HLA complex group 11 in cancer. Biomed Pharmacother 2021;143:112210. [PMID: 34563948 DOI: 10.1016/j.biopha.2021.112210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Kong YL, Xing Y, Li J, Liu CL, He XJ, Wang C, Chen JM, Kong LH, Han X, Zhang HY. Modified Procedures for ALPPS Based on a Risk-Reduced Strategy: Paralleled Clinical Evaluation at Multiple Institutions. Yonsei Med J 2021;62:918-27. [PMID: 34558871 DOI: 10.3349/ymj.2021.62.10.918] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Chen Z, Zou Y, Zhang Y, Chen Z, Wu F, Shi N, Jin H. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma. J Clin Lab Anal 2021;35:e24005. [PMID: 34523732 DOI: 10.1002/jcla.24005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
111 Khan H, Ni Z, Feng H, Xing Y, Wu X, Huang D, Chen L, Niu Y, Shi G. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling. Phytomedicine 2021;91:153706. [PMID: 34517264 DOI: 10.1016/j.phymed.2021.153706] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
112 Li L, Situ HJ, Ma WC, Liu X, Wang LL. Decreased DHRS1 expression is a novel predictor of poor survival in patients with hepatocellular carcinoma. Biomark Med 2021;15:1319-31. [PMID: 34498498 DOI: 10.2217/bmm-2021-0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Pan CT, Yu RS, Yang CJ, Chen LR, Wen ZH, Chen NY, Ou HY, Yu CY, Shiue YL. Sustained-Release and pH-Adjusted Alginate Microspheres-Encapsulated Doxorubicin Inhibit the Viabilities in Hepatocellular Carcinoma-Derived Cells. Pharmaceutics 2021;13:1417. [PMID: 34575492 DOI: 10.3390/pharmaceutics13091417] [Reference Citation Analysis]
114 Pang X, Gao X, Liu F, Jiang Y, Wang M, Li Q, Li Z. Xanthoangelol modulates Caspase-1-dependent pyroptotic death among hepatocellular carcinoma cells with high expression of GSDMD. Journal of Functional Foods 2021;84:104577. [DOI: 10.1016/j.jff.2021.104577] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Karabicici M, Azbazdar Y, Ozhan G, Senturk S, Firtina Karagonlar Z, Erdal E. Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Front Cell Dev Biol 2021;9:639779. [PMID: 34458250 DOI: 10.3389/fcell.2021.639779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
116 Zhang H, Yang X, Zhu L, Li Z, Zuo P, Wang P, Feng J, Mi Y, Zhang C, Xu Y, Jin G, Zhang J, Ye H. ASPM promotes hepatocellular carcinoma progression by activating Wnt/β-catenin signaling through antagonizing autophagy-mediated Dvl2 degradation. FEBS Open Bio 2021;11:2784-99. [PMID: 34428354 DOI: 10.1002/2211-5463.13278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
117 Chen B, Cha JH, Yan M, Cao N, Ye P, Yan X, Yang WH. ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin. Biochem Biophys Res Commun 2021;573:1-8. [PMID: 34375763 DOI: 10.1016/j.bbrc.2021.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
118 Li H, Gao J, Zhang S. Functional and Clinical Characteristics of Cell Adhesion Molecule CADM1 in Cancer. Front Cell Dev Biol 2021;9:714298. [PMID: 34395444 DOI: 10.3389/fcell.2021.714298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Weng X, Lu XJ. Circular RNA and human diseases: Basic research and translational implications. Cell Signal 2021;86:110100. [PMID: 34329729 DOI: 10.1016/j.cellsig.2021.110100] [Reference Citation Analysis]
120 Hu X, Zhu H, Shen Y, Zhang X, He X, Xu X. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:696705. [PMID: 34367979 DOI: 10.3389/fonc.2021.696705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
121 Ge Y, Shu J, Shi G, Yan F, Li Y, Ding H. miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7. J Immunol Res 2021;2021:9920786. [PMID: 34337085 DOI: 10.1155/2021/9920786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Gao X, Zhao C, Zhang N, Cui X, Ren Y, Su C, Wu S, Yao Z, Yang J. Genetic expression and mutational profile analysis in different pathologic stages of hepatocellular carcinoma patients. BMC Cancer 2021;21:786. [PMID: 34238242 DOI: 10.1186/s12885-021-08442-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
123 Gan G, Shi Z, Liu D, Zhang S, Zhu H, Wang Y, Mi J. 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. Cell Death Discov 2021;7:173. [PMID: 34230478 DOI: 10.1038/s41420-021-00561-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
124 Yang Q, Li W, Chen Z, Chen D, Du Y, Lang L, Ye Z, Shen S, Lei Z, Zhang S. Water-cooled microwave ablation array for bloodless rapid transection of the liver. Int J Hyperthermia 2021;38:823-9. [PMID: 34058947 DOI: 10.1080/02656736.2021.1912411] [Reference Citation Analysis]
125 Qin M, Wang D, Fang Y, Zheng Z, Liu X, Wu F, Wang L, Li X, Hui B, Ma S, Tang W, Pan X. Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma. Front Oncol 2021;11:647854. [PMID: 34235074 DOI: 10.3389/fonc.2021.647854] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
126 Ricci AD, Rizzo A, Bonucci C, Tavolari S, Palloni A, Frega G, Mollica V, Tober N, Mazzotta E, Felicani C, Serra C, Brandi G. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo 2020;34:3421-9. [PMID: 33144450 DOI: 10.21873/invivo.12181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
127 Moon H, Ro SW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3026. [PMID: 34204242 DOI: 10.3390/cancers13123026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 29.0] [Reference Citation Analysis]
128 Xu H, Xiong C, Chen Y, Zhang C, Bai D. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Bioengineered 2021;12:2664-75. [PMID: 34115569 DOI: 10.1080/21655979.2021.1938470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
129 Ma Y, Sun W, Zhang Q, Gao B, Cai W, Liu Q, Liao J, Wang X. lncRNA BSG-AS1 is hypoxia-responsive and promotes hepatocellular carcinoma by enhancing BSG mRNA stability. Biochem Biophys Res Commun 2021;566:101-7. [PMID: 34119821 DOI: 10.1016/j.bbrc.2021.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
130 Cheng Z, Ni Q, Qin L, Shi Y. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. Braz J Med Biol Res 2021;54:e10390. [PMID: 34076140 DOI: 10.1590/1414-431X2020e10390] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Xu Q, Hu Y, Chen S, Zhu Y, Li S, Shen F, Guo Y, Sun T, Chen X, Jiang J, Huang W. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:683240. [PMID: 34124163 DOI: 10.3389/fmolb.2021.683240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
132 Guo M, Li N, Zheng J, Wang W, Wu Y, Han X, Guo J, Chen W, Bai Z, Bai W, Wu J. Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway. Can J Gastroenterol Hepatol 2021;2021:5596712. [PMID: 34123955 DOI: 10.1155/2021/5596712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
133 Li L, Xia S, Shi X, Chen X, Shang D. The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Sci Rep 2021;11:10728. [PMID: 34021184 DOI: 10.1038/s41598-021-89747-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Yang G, Wang G, Xiong Y, Sun J, Li W, Tang T, Li J. CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial‑mesenchymal transition. Mol Med Rep 2021;24:483. [PMID: 33907851 DOI: 10.3892/mmr.2021.12122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
135 Darden M, Parker G, Monlezun D, Anderson E, Buell JF. Race and Gender Disparity in the Surgical Management of Hepatocellular Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Program Registry. World J Surg 2021;45:2538-45. [PMID: 33893525 DOI: 10.1007/s00268-021-06091-7] [Reference Citation Analysis]
136 Hu J, Cai D, Zhao Z, Zhong GC, Gong J. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Front Oncol 2021;11:659676. [PMID: 33937074 DOI: 10.3389/fonc.2021.659676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
137 Moon H, Ro SW. Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. J Liver Cancer 2021;21:1-11. [DOI: 10.17998/jlc.21.1.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Zhang Z, Chen P, Xie H, Cao P. Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma. Front Oncol 2021;11:654185. [PMID: 33842367 DOI: 10.3389/fonc.2021.654185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
139 Peng X, Chen R, Cai S, Lu S, Zhang Y. SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC. Front Oncol 2021;11:650355. [PMID: 33777811 DOI: 10.3389/fonc.2021.650355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
140 Hong Y, Ye M, Wang F, Fang J, Wang C, Luo J, Liu J, Liu J, Liu L, Zhao Q, Chang Y. MiR-21-3p Promotes Hepatocellular Carcinoma Progression via SMAD7/YAP1 Regulation. Front Oncol 2021;11:642030. [PMID: 33763375 DOI: 10.3389/fonc.2021.642030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
141 Song K, He F, Xin Y, Guan G, Huo J, Zhu Q, Fan N, Guo Y, Zang Y, Wu L. TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy. Pharmgenomics Pers Med 2021;14:269-78. [PMID: 33623416 DOI: 10.2147/PGPM.S294307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Wang H, Wang P, Xu M, Song X, Wu H, Evert M, Calvisi DF, Zeng Y, Chen X. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression. Cell Death Dis 2021;12:200. [PMID: 33608500 DOI: 10.1038/s41419-021-03488-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
143 Zhou J, Wang W, Li Q. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. J Exp Clin Cancer Res 2021;40:73. [PMID: 33596985 DOI: 10.1186/s13046-021-01873-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
144 Chen X, Cheng B, Dai D, Wu Y, Feng Z, Tong C, Wang X, Zhao J. Heparanase induces necroptosis of microvascular endothelial cells to promote the metastasis of hepatocellular carcinoma. Cell Death Discov 2021;7:33. [PMID: 33597510 DOI: 10.1038/s41420-021-00411-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
145 Yang Y, Mao F, Guo L, Shi J, Wu M, Cheng S, Guo W. Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP. Dig Liver Dis 2021;53:474-85. [PMID: 33563583 DOI: 10.1016/j.dld.2021.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
146 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
147 Wehling C, Dill MT, Olkus A, Springfeld C, Chang DH, Naumann P, Longerich T, Kratochwil C, Mehrabi A, Merle U, Pfeiffenberger J, Rupp C, Weiss KH, Mieth M. Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. J Cancer Res Clin Oncol 2021;147:2471-81. [PMID: 33537908 DOI: 10.1007/s00432-021-03528-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
148 Aitcheson G, Pillai A, Dahman B, John BV. Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Curr Hepatol Rep 2021;:1-11. [PMID: 33552839 DOI: 10.1007/s11901-021-00560-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
149 Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res 2021;149:257-94. [PMID: 33579425 DOI: 10.1016/bs.acr.2020.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 19.0] [Reference Citation Analysis]
150 Huang TH, Lin MT, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract 2021;75:e13945. [PMID: 33338308 DOI: 10.1111/ijcp.13945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Ding L, Liang X. Ras related GTP binding D promotes aerobic glycolysis of hepatocellular carcinoma. Ann Hepatol 2021;23:100307. [PMID: 33434687 DOI: 10.1016/j.aohep.2021.100307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
152 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
153 Oldhafer KJ, Seehofer D, Rademacher S, Sucher R, Werner J, Bucher JN, Guba MO, Schlitt HJ, Schmelzle M, Schöning W, Raschzok N, Pratschke J, Wagner D, Schemmer P. Individualisierte Leberchirurgie. Viszeralchirurgische Operationen und technische Varianten 2021. [DOI: 10.1007/978-3-662-60475-5_7] [Reference Citation Analysis]
154 Xu Y, Jiang Q, Liu H, Xiao X, Yang D, Saw PE, Luo B. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration. J Immunol Res 2020;2020:8835393. [PMID: 33490290 DOI: 10.1155/2020/8835393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
155 Zhang J, Yang G, Li Q, Xie F. Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma. Oncol Lett 2021;21:92. [PMID: 33376525 DOI: 10.3892/ol.2020.12353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
156 Shao XY, Dong J, Zhang H, Wu YS, Zheng L. Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma. Front Mol Biosci 2020;7:577460. [PMID: 33344502 DOI: 10.3389/fmolb.2020.577460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
157 Buonaguro FM, Botti G, Ascierto PA, Pignata S, Ionna F, Delrio P, Petrillo A, Cavalcanti E, Di Bonito M, Perdonà S, De Laurentiis M, Fiore F, Palaia R, Izzo F, D'Auria S, Rossi V, Menegozzo S, Piccirillo M, Celentano E, Cuomo A, Normanno N, Tornesello ML, Saviano R, Barberio D, Buonaguro L, Giannoni G, Muto P, Miscio L, Bianchi AAM; and the INT-Pascale COVID-19 Crisis Unit. The clinical and translational research activities at the INT - IRCCS "Fondazione Pascale" cancer center (Naples, Italy) during the COVID-19 pandemic. Infect Agent Cancer 2020;15:69. [PMID: 33292365 DOI: 10.1186/s13027-020-00330-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
158 Walesky CM, Kolb KE, Winston CL, Henderson J, Kruft B, Fleming I, Ko S, Monga SP, Mueller F, Apte U, Shalek AK, Goessling W. Functional compensation precedes recovery of tissue mass following acute liver injury. Nat Commun 2020;11:5785. [PMID: 33214549 DOI: 10.1038/s41467-020-19558-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
159 Wang J, Wang W, Tang Q, Lu L, Luo Z, Li W, Lu Y, Pu J. Long Non-coding RNA lnc-GNAT1-1 Suppresses Liver Cancer Progression via Modulation of Epithelial-Mesenchymal Transition. Front Genet 2020;11:1029. [PMID: 33193591 DOI: 10.3389/fgene.2020.01029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
160 Zeng Z, Lan J, Lei S, Yang Y, He Z, Xue Y, Chen T. Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells. Onco Targets Ther 2020;13:11697-709. [PMID: 33244237 DOI: 10.2147/OTT.S240535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Huo J, Wu L, Zang Y. A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:581354. [PMID: 33282911 DOI: 10.3389/fmolb.2020.581354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
162 Li K, Cao J, Zhang Z, Chen K, Ma T, Yang W, Yang S, Rao J, Zhang K. Circular RNA circGSK3B Promotes Cell Proliferation, Migration, and Invasion by Sponging miR-1265 and Regulating CAB39 Expression in Hepatocellular Carcinoma. Front Oncol 2020;10:598256. [PMID: 33262952 DOI: 10.3389/fonc.2020.598256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
163 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Pan YX, Fu YZ, Hu DD, Long Q, Wang JC, Xi M, Liu SL, Xu L, Liu MZ, Chen MS, Zhang YJ. Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol. 2020;10:1639. [PMID: 33194569 DOI: 10.3389/fonc.2020.01639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
165 Zhang DY, Sun QC, Zou XJ, Song Y, Li WW, Guo ZQ, Liu SS, Liu L, Wu DH. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2. J Exp Clin Cancer Res 2020;39:229. [PMID: 33121524 DOI: 10.1186/s13046-020-01748-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
166 Tang B, Zhu J, Li J, Fan K, Gao Y, Cheng S, Kong C, Zheng L, Wu F, Weng Q, Lu C, Ji J. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signal 2020;18:174. [PMID: 33115468 DOI: 10.1186/s12964-020-00663-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 31.0] [Reference Citation Analysis]
167 Lu Q, Gao J, Tang S, Li Z, Wang X, Deng C, Hu J, Tao Y, Wang Q. Integrated RNA Sequencing and Single-Cell Mass Cytometry Reveal a Novel Role of LncRNA HOXA-AS2 in Tumorigenesis and Stemness of Hepatocellular Carcinoma. Onco Targets Ther 2020;13:10901-16. [PMID: 33149607 DOI: 10.2147/OTT.S272717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
168 Jin C, Li Y, Su Y, Guo Z, Wang X, Wang S, Zhang F, Zhang Z, Shao J, Zheng S. Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26. Cell Death Dis 2020;11:844. [PMID: 33041323 DOI: 10.1038/s41419-020-03048-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
169 Rogger TM, Michielan A, Sferrazza S, Pravadelli C, Moser L, Agugiaro F, Vettori G, Seligmann S, Merola E, Maida M, Ciarleglio FA, Brolese A, de Pretis G. Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. World J Gastroenterol 2020; 26(35): 5375-5386 [PMID: 32994695 DOI: 10.3748/wjg.v26.i35.5375] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Phatruengdet T, Intakhad J, Tapunya M, Chariyakornkul A, Hlaing CB, Wongpoomchai R, Pilapong C. MRI contrast enhancement of liver pre-neoplasia using iron-tannic nanoparticles. RSC Adv 2020;10:35419-25. [PMID: 35515681 DOI: 10.1039/d0ra07308c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Zhao Y, Xue C, Xie Z, Ouyang X, Li L. Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma. Cell Prolif 2020;53:e12908. [PMID: 32951278 DOI: 10.1111/cpr.12908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
172 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
173 Chen R, Zhang Y. EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. J Cell Mol Med 2020;24:12107-18. [PMID: 32935479 DOI: 10.1111/jcmm.15852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
174 Li J, Yang GS, Sun KJ, Ma Y, Bi XW, Han X. Clinical evaluation of modified ALPPS procedures based on risk-reduced strategy for staged hepatectomy. Ann Hepatol 2021;20:100245. [PMID: 32877762 DOI: 10.1016/j.aohep.2020.08.063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Huang XY, Li H. Correlation of blood flow in hepatocellular carcinoma with serum high mobility group box protein 1 and microvascular invasion: A preliminary study. Shijie Huaren Xiaohua Zazhi 2020; 28(16): 807-812 [DOI: 10.11569/wcjd.v28.i16.807] [Reference Citation Analysis]
176 Guo P, Pi C, Zhao S, Fu S, Yang H, Zheng X, Zhang X, Zhao L, Wei Y. Oral co-delivery nanoemulsion of 5-fluorouracil and curcumin for synergistic effects against liver cancer. Expert Opinion on Drug Delivery 2020;17:1473-84. [DOI: 10.1080/17425247.2020.1796629] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
177 Wang J, Li J, Chen L, Fan Z, Cheng J. MicroRNA-499 Suppresses the Growth of Hepatocellular Carcinoma by Downregulating Astrocyte Elevated Gene-1. Technol Cancer Res Treat 2020;19:1533033820920253. [PMID: 32691684 DOI: 10.1177/1533033820920253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
178 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 18.5] [Reference Citation Analysis]
179 Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, Yan P, Liang X, Yu T, Wang Y, Cai X. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:11466-84. [PMID: 32579541 DOI: 10.18632/aging.103231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
180 Marin JJG, Macias RIR, Monte MJ, Romero MR, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano AG, Espinosa-Escudero R, Reviejo M, Bohorquez LH, Briz O. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1663. [PMID: 32585893 DOI: 10.3390/cancers12061663] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 29.5] [Reference Citation Analysis]
181 Lin S, Zhuang J, Zhu L, Jiang Z. Matrine inhibits cell growth, migration, invasion and promotes autophagy in hepatocellular carcinoma by regulation of circ_0027345/miR-345-5p/HOXD3 axis. Cancer Cell Int 2020;20:246. [PMID: 32549793 DOI: 10.1186/s12935-020-01293-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
182 Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
183 Xu B, Zhang Y, Yang H, Liu T, Lu Y, Xu Y, Zhang Q, Li X, Huang Z, Zhang Y, Webster TJ. siVEGF-loaded nanoparticle uptake by tumor-associated vascular endothelial cells for hepatocellular carcinoma. Nanomedicine (Lond) 2020. [PMID: 32458768 DOI: 10.2217/nnm-2020-0082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Cui X, Jiang X, Wei C, Xing Y, Tong G. Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/β-catenin axis. Environ Toxicol Pharmacol 2020;78:103397. [PMID: 32417721 DOI: 10.1016/j.etap.2020.103397] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
185 Ozcan M, Altay O, Lam S, Turkez H, Aksoy Y, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach. Adv Biosyst 2020;4:e2000030. [PMID: 32529800 DOI: 10.1002/adbi.202000030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
186 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
187 Hu JW, Ding GY, Fu PY, Tang WG, Sun QM, Zhu XD, Shen YH, Zhou J, Fan J, Sun HC, Huang C. Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. Biomed Res Int 2020;2020:6784138. [PMID: 32280695 DOI: 10.1155/2020/6784138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
188 Nekvindova J, Mrkvicova A, Zubanova V, Hyrslova Vaculova A, Anzenbacher P, Soucek P, Radova L, Slaby O, Kiss I, Vondracek J, Spicakova A, Bohovicova L, Fabian P, Kala Z, Palicka V. Hepatocellular carcinoma: Gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. Biochem Pharmacol 2020;177:113912. [PMID: 32173367 DOI: 10.1016/j.bcp.2020.113912] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
189 Huang S, Zhang C, Sun C, Hou Y, Zhang Y, Tam NL, Wang Z, Yu J, Huang B, Zhuang H, Zhou Z, Ma Z, Sun Z, He X, Zhou Q, Hou B, Wu L. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:3025-41. [PMID: 32045367 DOI: 10.18632/aging.102797] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
190 Liu Y, Yang Y, Luo Y, Wang J, Lu X, Yang Z, Yang J. Prognostic potential of PRPF3 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:912-30. [PMID: 31926109 DOI: 10.18632/aging.102665] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
191 Zhang P, Wang Q, Lin Z, Yang P, Dou K, Zhang R. Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake.Onco Targets Ther. 2019;12:11751-11763. [PMID: 32021249 DOI: 10.2147/OTT.S235667] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
192 Pisla D, Calin V, Birlescu I, Hajjar NA, Gherman B, Radu C, Plitea N. Risk Management for the Reliability of Robotic Assisted Treatment of Non-resectable Liver Tumors. Applied Sciences 2020;10:52. [DOI: 10.3390/app10010052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
193 Liao J, Zeng D, Li J, Hua Q, Xiao Z, He C, Mao K, Zhu L, Chu Y, Wen W, Zheng L, Wu Y. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int 2020;14:80-95. [DOI: 10.1007/s12072-019-10003-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
194 Massimi M, Ragusa F, Cardarelli S, Giorgi M. Targeting Cyclic AMP Signalling in Hepatocellular Carcinoma. Cells 2019;8:E1511. [PMID: 31775395 DOI: 10.3390/cells8121511] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
195 Liu Z, Chen JY, Zhong Y, Xie L, Li JS. lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11. Braz J Med Biol Res. 2019;52:e8631. [PMID: 31531526 DOI: 10.1590/1414-431x20198631] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
196 El-Koubani O, McCann M, Christmas D, Khanna A, von Maydell A. Radiofrequency-Assisted Liver Resection Versus Clamp-Crush Liver Resection: Protocol for an Updated Meta-Analysis and Systematic Review. JMIR Res Protoc 2019;8:e13437. [PMID: 31432783 DOI: 10.2196/13437] [Reference Citation Analysis]
197 Wehling C, Hornuss D, Schneider P, Springfeld C, Hoffmann K, Chang D, Naumann P, Mieth M, Longerich T, Kratochwil C, Mehrabi A, Gauss A, Weiss KH, Pfeiffenberger J. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2019;145:2761-9. [DOI: 10.1007/s00432-019-03005-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
198 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
199 Fan W, Yang X, Huang F, Tong X, Zhu L, Wang S. Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer. Oncol Lett 2019;18:3218-26. [PMID: 31452799 DOI: 10.3892/ol.2019.10673] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
200 Van Haele M, Snoeck J, Roskams T. Human Liver Regeneration: An Etiology Dependent Process. Int J Mol Sci 2019;20:E2332. [PMID: 31083462 DOI: 10.3390/ijms20092332] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
201 章 文. Molecular Markers and Recurrence of Hepatocellular Carcinoma after Liver Transplantation. ACM 2019;09:310-318. [DOI: 10.12677/acm.2019.93047] [Reference Citation Analysis]